Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Carisma Therapeutics Inc CARM

Healthcare Biotechnology
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing its proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. It is developing a pipeline of product candidates, with an initial focus on advancing multiple ex vivo autologous and in vivo CAR-M therapies for the... see more

Recent & Breaking News (NDAQ:CARM)

Sesen Bio Reports Third Quarter 2018 Financial Results and Planned VISTA Trial Readouts

Business Wire November 8, 2018

Sesen Bio to Present Three-month VISTA Trial Data at Global Congress on Bladder Cancer 2018

Business Wire September 20, 2018

Sesen Bio Reports Second Quarter 2018 Financial Results and Pipeline Updates

Business Wire August 14, 2018

Sesen Bio Announces Vicinium Granted Fast Track Designation by FDA for Treatment of Non-Muscle Invasive Bladder Cancer

Business Wire August 9, 2018

Sesen Bio Announces CEO and Board Transitions as Company Prepares for 12-Month VISTA Trial Data and Regulatory Submission in 2019

Business Wire August 7, 2018

Sesen Bio to Present at the Canaccord Genuity 38th Annual Growth Conference

Business Wire August 2, 2018

Sesen Bio Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares of Common Stock

Business Wire June 4, 2018

Sesen Bio Announces Pricing of Public Offering of Common Stock

Business Wire May 30, 2018

Sesen Bio Announces Proposed Public Offering of Common Stock

Business Wire May 30, 2018

Sesen Bio to Present at the Jefferies 2018 Global Healthcare Conference

Business Wire May 29, 2018

Phase 3 Registration Trial for Non-Muscle Invasive Bladder Cancer Achieves 42% Complete Response Rate at Three Months in Carcinoma in Situ Patients

Business Wire May 21, 2018